“Possibly life-threatening (SAEs) in organ systems THAT

New Post Public Reply Private Reply Replies (2) Message Board
ClosetInvestor JLang #65553
923
“Possibly life-threatening (SAEs) in organ systems THAT ARE CONFIRMED INDICATIONS IN CV19 are.”

So you admit that the side effects (including SAEs) are possible and not likely to occur in every patient? I appreciate that. Steven Johnson’s has been reported as a side effect of ibuprofen but that doesn’t stop it from being sold over the counter.

“The amount of liability involved with throwing random medications at patients is immense..”

You obviously have not prescribed medications before. Medications aren’t “thrown randomly” at patients and instead, like I said before, are carefully chosen. More than just occasionally the best drug for a certain diagnosis has side effects which requires different levels of monitoring in the hospital or on an outpatient level.

“Any ****head dismissing the possibility of exacerbating organ damage or death as a result is playing God, and falling woefully short.”

Again, those who’ve prescribed medications always make a cost benefit analysis when choosing a medication. And again, even patients with already existing organ damage need mediation to prevent them from circling the drain, even if that results in other side effects.

“there have been several rabid cheerleaders for Mara”

There are few researchers and/or doctors with the credentials and expertise of Dr. BP. His choice to study the use of maraviroc in LHs was not rabid nor the act of a cheerleader. He doesn’t have access to leronlimab so he chose the next available CCR5 MAB. Pretty simple.

Also, maraviroc has side effects but isn’t as damaging as CYDY investors make it out to be. There were only 2 cases of acute hepatocellular injury reported in the trials. Additionally, an NIH study found that, “therapy with maraviroc was associated with alanine aminotransferase (ALT) elevations in up to 10% of patients, but elevations above 5 times normal are less common. Furthermore, rates of ALT elevations with maraviroc were similar to rates in comparator groups receiving similar background optimized antiretroviral therapy [2.6% vs 3.4% above 5 times ULN in one study and 3.9% vs 4.0% in a second]. The serum aminotransferase abnormalities that occur during maraviroc therapy are usually mild and self-limited, not requiring dose modification or discontinuation.“ That’s not my opinion, but facts published by the NIH.

You know what else cause elevations in ALT and AST in up to 15% of patients? You guessed it, ibuprofen.

“That might all be a bunch of gibberish to you, but it sounds like a list of CV19 indications to anyone without an ulterior agenda.”

No ulterior agendas here. I’ve, been a CYDY investor since 2015 and I’m very happy with my returns and current position.
1

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lepage Millwork to Acquire Custom Window Maker Fenêtres MQ

Updated Category News Views 64

Big Move in Windows: Lepage Eyes Fenêtres MQ Dust off those old window ledgers, folks, because we've got a shake-up in the custom luxury window game. Lepage Millwork, a family-run titan in the North American fenestration scene, is gearing up to take over Fenêtres MQ from the big shots over at Andersen. We're talking about an ownership shift set to seal the deal by...

Continue Reading
University of Phoenix Leads Credentialing Dialogue at Summit

Updated Category News Views 42

Credentials in the Spotlight at PESC Summit When you're talking credentials and data standards at the PESC Summit, you've got a gathering of big brains aiming to steer the wild ride of higher education into the future. This October, University of Phoenix leaders stepped up to the plate in Scottsdale, Arizona, delivering a frank talk about the role of credentials in...

Continue Reading
Co-op Giants Earn $309B: Key Players Spotlighted

Updated Category News Views 188

Co-ops Punch Above Their Weight Forget the tired stereotypes about co-ops as small-time players. The NCB Co-op 100® Report lands like a punch with a staggering revelation: $309 billion in revenue for 2025. That's no small potatoes, and it shows these cooperatives, sprinkled across agriculture, finance, and beyond, are no shy creatures—they're major contenders in...

Continue Reading
ADT Shareholders Face Legal Scrutiny in M&A Deal

Updated Category News Views 19

ADT Shareholders on High Alert Listen up, folks. Anyone holding shares in ADT Inc. (NYSE: ADT) needs to sharpen their pencils and start crunching numbers. This isn't the time to sit back and coast. A M&A Class Action investigation is brewing, and it's centered on ADT's sale to Thrive Holdings. The $10.00 per share buyout offer might look neat and tidy, but there's more to...

Continue Reading
Class Action Looms Over Tenax Therapeutics Investors

Updated Category News Views 51

Shareholders in the Crosshairs Every once in a while, the market serves up a cold dish of reality, and folks owning Tenax Therapeutics (NASDAQ:TENX) are facing just that. A class action is casting a long shadow, targeting those who bought in between November 13, 2023, and August 7, 2026. It's the kind of headache that no investor wakes up hoping for. The Allegations: When...

Continue Reading
PRTH Shareholder Concerns Amid Merger Investigation

Updated Category News Views 79

Behind Closed Doors: PRTH's Merger Drama Unfolds The market's got its share of tricky maneuvers and right now, Priority Technology Holdings, Inc. (NASDAQ:PRTH) is under the magnifying glass. Levi & Korsinsky, LLP has kicked off an investigation into the nitty-gritty of PRTH's acquisition by its largest shareholder—none other than their own Chairman and CEO, Thomas C....

Continue Reading
Investigations Target PAG, BRBS, PSNL for Fair Shareholder Deals

Updated Category News Views 64

Unpacking the Shareholder's Dilemma in Major Transactions Alright, folks, let's dig into this mess with our favorite Wall Street magnifying glass. We've got Penske Automotive Group (NYSE: PAG), Blue Ridge Bankshares (NYSE: BRBS), and Personalis, Inc. (NASDAQ: PSNL) under the spotlight, each locking themselves into deals that might not exactly scream 'fair play' for the...

Continue Reading
The Sift: Slickdeals’ Game-Changing Black Friday Tool

Updated Category News Views 272

Revolutionizing Black Friday Planning Off we go, diving headfirst into the chaotic whirlpool that is Black Friday shopping. Slickdeals seems to think they’ve got the golden ticket with The Sift, and I can't say they're wrong. Instead of the traditional paper ad scans we've been sifting through since the dawn of time, The Sift brings all announced deals into one...

Continue Reading
Holiday Shoppers Eye Payment Options Amid Tight Budgets

Updated Category News Views 59

Shoppers Feel the Squeeze As Holidays Approach Hope you brought your umbrella because the holiday season is going to be awash with financial strain and stress for many consumers. According to the latest ETA-TSG Consumer Holiday Spending Study, 44% of consumers are more financially stressed this year compared to last, and the numbers aren't getting any rosier from there....

Continue Reading
Hisense's RGB MiniLED TVs: Redefining Halloween Viewing

Updated Category News Views 80

A New Dimension to Halloween's Visuals You ever notice how some TVs just can’t do justice to a Halloween flick? It’s all about the details—those rich, spooky colors and the perfectly balanced light and shadow. The nuance in the shadowy folds of a cape or the eerie glow of a lantern is crucial. Hisense's RGB MiniLED technology is showing up just in time to rescue...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Developments in Titanium Powder Production by PyroGenesis

Updated Category News Views 156

Significant Contract for Titanium Powder Production PyroGenesis Inc., a pioneer in ultra-high temperature processes and a leading technology provider to heavy industry and defense, is making waves in the additive manufacturing sector. The company has announced an initial order for 'fine cut' titanium powder, which has been produced using their advanced NexGen™ plasma...

Continue Reading
Exploring The Impressive Returns of The Hartford Insurance

Updated Category News Views 254

Understanding The Hartford Insurance Group's Growth The Hartford Insurance Group (NYSE: HIG) has displayed impressive market performance over the past five years, outpacing overall market gains significantly. With an annualized return of 26.43%, this company has offered a noteworthy 12.44% lead over the market average. Current market capitalization stands at approximately...

Continue Reading
Exciting New Consumer Product Launches and Trends This Week

Updated Category News Views 520

Highlights of this Week’s Major Consumer Announcements This week brings an exciting selection of consumer and retail news that you won’t want to miss. From the world of fragrances to the latest Halloween trends, here’s a closer look at some captivating announcements that are making waves. Ariana Grande’s Wicked-Inspired Fragrances Ariana Grande has taken things to...

Continue Reading
Occidental Petroleum's Significant Debt Reduction Achievements

Updated Category News Views 274

Occidental Petroleum's Debt Reduction Strategy In a significant stride towards enhancing its financial health, Occidental Petroleum (NYSE: OXY) announced remarkable progress in its debt reduction efforts, achieving a key target of $4.5 billion by the end of 2024. This noteworthy milestone positions the company well as it navigates the complexities of the evolving energy...

Continue Reading
Aptose Unveils Promising New Therapy for AML Patients

Updated Category News Views 218

Aptose Unveils Promising New Therapy for AML Patients In a groundbreaking development, Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) recently announced that the initial patients have been dosed in the TUSCANY Phase 1/2 trial. This innovative trial evaluates the effectiveness of tuspetinib (TUS) in combination with venetoclax (VEN) and azacitidine (AZA). This trio...

Continue Reading